Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways
The purpose of this study is to demonstrate that combined stereotactic body radiotherapy and radiofrequency ablation is safe for patients with lung tumors near central airways.
Lung Cancer
RADIATION: Stereotactic Body Radiation|RADIATION: Radiofrequency Ablation
Achieve at most of 20% subacute or chronic grade 3 or higher lng, cardiac, or upper GI toxicity rate in patients treated with SBRT/RFA., 3 years
Achieve no more than 15% decline from the pre-treatment pulmonary function parameter (FEV1, DLCO) post-SBRT/RFA., 3 years|Achieve at least a 80% one-year local control (LC) rate by RECIST criterion or PET response (if applicable)., 3 years|Progression-free survival, 3 years|Overall survival, 3 years|Concentration of serum TGF-B as early biomarker for treatment-inducted normal tissue injury, 3 years|Concentration of serum VEGF as an early biomarker for response, 3 years
The purpose of this study is to demonstrate that combined stereotactic body radiotherapy and radiofrequency ablation is safe for patients with lung tumors near central airways.